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Background: Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health.
Messages promoting social welfare have been shown to increase vaccination intentions, and it has been
recommended that health professionals communicate the socially beneficial aspects of vaccination. We provide the
first test whether this prosocial vaccination hypothesis applies to actual vaccination behaviour of high-risk patients.
Methods: In a field experiment at a tertiary care public hospital in Istanbul, Turkey, we compare the effects of two
motivational messages for promoting vaccination. Using a between-subjects single-blind experimental design
patients were randomly assigned to frames emphasizing the vaccine’s benefits to self (n = 125) or social benefits
(n = 119). Free influenza vaccination was offered to each patient.
Results: Among 222 patients who were not vaccinated for the season prior to the study (72% medically assessed
to be at high risk), 42% in the self-benefit frame chose to receive a vaccination compared with 34% in the social-
benefits frame, but the difference was not statistically significant (aOR = 1.63, 95% CI 0.90 to 2.95, p = 0.108). Reasons
for vaccination focused primarily on self-benefit (67%) rather than social-benefit (5%). Exploratory analysis showed
that the effect of messages depended on patient perception of risk group membership (aORHigh / aORLow = 5.59,
95% CI 1.30 to 24.05, p = 0.021). In particular, emphasis on self-benefit was more influential among patients who
perceived themselves to be in the risk group (aOR = 6.22, 95% CI 1.69 to 22.88, p = 0.006).
Conclusions: In contrast to the literature observing intentions of low-risk populations, we found no evidence that
social-benefit motivates actual vaccination behaviour among a high-risk patient population. Instead, those who self-
categorize as being in the high risk group are more motivated by the self-benefit message. Our results suggest that
a stratified approach can improve coverage: even if an emphasis on social-benefit could be effective among low-
risk groups, an emphasis on self-benefit holds more promise for increasing vaccination in medical organizational
settings where high-risk groups are prevalent.
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Influenza poses a serious threat to human health, annu-
ally resulting in 250,000 to 500,000 deaths worldwide
[1]. Even though the influenza vaccine is widely available
and affordable, its global uptake remains low [2]. Mean-
while, the negative impact of influenza is expected to
grow due to rapid increases in high-risk populations
such as the elderly [3]. As long as herd immunity re-
mains a distant goal, vaccination of high-risk populations
will remain a public health priority [4], despite vaccina-
tion’s limited effectiveness in such populations [5]. Fur-
thermore, even with accrued knowledge of the social
and psychological correlates of vaccination [3, 6–8],
causal pathways that can be exploited to increase uptake
remain poorly understood, rendering the behavioural
impact of public policies ambiguous. In particular, ex-
perimental investigations of vaccination behaviour
among high-risk patient groups are rare. Our study
hence focuses on behavioural interventions to motivate
vaccination among those at heightened risk of harm
from influenza infection.
A promising candidate for promoting vaccination is
the idea of harnessing prosocial motives (e.g., care for
family, friends and community) by highlighting the so-
cial benefits of vaccination [9]. Various studies report
evidence that messages about the social benefits of vac-
cination strengthen the intentions to vaccinate [10–12].
Based on these findings, it was recently recommended
that professionals can increase vaccine uptake by em-
phasizing its social benefits [13]. We refer to this view as
the prosocial vaccination hypothesis. Given accumulated
evidence for the prevalence of prosocial motives in other
domains [14, 15], the idea is promising. However, evi-
dence for the prosocial vaccination hypothesis remains
limited for two reasons.
First, the general applicability of the prosocial vaccin-
ation hypothesis is not well-established. In particular,
the effects of health behaviour interventions will likely
depend on psychological differences [7, 16, 17] such as
risk perceptions [18–21]. Supporting this view, prosocial
sensitivities have been found to decrease with disease
risk [22], and the effect of motivational messages have
been found to depend on the relative prevalence of high
and low risk groups [23].
Second, most experiments investigating social benefit
as a vaccination motive measured intentions among low-
risk populations in artificial settings [9, 11, 12, 22, 23].
However, intentions do not always predict behaviour
well [24–26]. In particular, hypothetical scenarios may
enhance a preference to appear altruistic [27, 28] and
thus limit generalizability of previous evidence [29, 30].
The only two field experiments testing the hypothesis
found no advantage of prosocial messages in promoting
vaccination, yet they studied the behaviour of health-care professionals and not the more prevalent patient
groups [31, 32]. It hence remains unknown whether so-
cial welfare motivates actual vaccination uptake of high-
risk groups in real-world settings [9].
To overcome these two limitations, we conducted the
first field experiment in a hospital setting that observed
the causal effects of prosocial messages on the vaccin-
ation behaviour of high-risk patients in a natural
environment. We used two motivational frame manipu-
lations, one emphasizing the self-benefit and the other
emphasizing the social-benefit of vaccination. The two
frames used in our experiment were based on actual vac-
cine promotion pamphlets employed by the UK National
Health Service. The prosocial vaccination hypothesis
predicts that emphasizing the social benefits of vaccin-
ation will increase uptake compared to an emphasis only
on benefits to self.
Perceived risk has been shown to be a more powerful
predictor of vaccination than objective risk [33]. We
compare objective (medically diagnosed) and subjective
(patient perceived) measures of risk group status, indicat-
ing high or low risk of severe harm due to influenza re-
lated illnesses [8], and explore whether they moderate
the effect of prosocial messages on vaccination behav-
iour. We provide self-reported reasons for vaccine ac-
ceptance and refusal as well as a rationale why social-
benefit messages may be counterproductive for those
who perceive themselves as being in the risk group for
influenza complications.Methods
Participants
Participants were recruited at a tertiary care public hos-
pital in Istanbul from November 2016 to March 2017.
Two hundred and fifty-one adult patients were
approached during the twenty-week study period and
244 of them (97%) agreed to participate. One hundred
and sixteen patients were female (48%), the median age
was 60 and only 54 patients had education levels higher
than primary school (22%). Patients were recruited from
the Internal Medicine (41%), Neurology (28%), Infectious
Diseases (23%), Physical Medicine (7%) and Dermatology
(1%) wards. Eighty-six participants were diagnosed with
an infectious disease at admission to the hospital (35%).
The two most common infection diagnoses were pneu-
monia (42%) and urinary tract infections (17%). Other
diagnoses of infections included skin and soft tissue in-
fections, intra-abdominal infections, viral hepatitis, cen-
tral nervous system infections, HIV infection, etc.
Patients were randomly assigned to either the self-
benefit or the social-benefit message. Twenty-two of the
244 patients (9%) reported that they were already vacci-
nated for the season (see Fig. 1 & Table 1).
Fig. 1 Study flow
1The pamphlet is publicly available at https://www.nhsdirect.wales.nhs.
uk/pdfs/Main%20Flu%20Poster%20WEB.pdf
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Because there is no previous comparison of the effects
of self- and social-benefit on actual patient vaccination
behaviour, we assumed a medium effect size (aOR = 3.0
or a Cohen’s d of 0.60) [34, 35]. This value is smaller
than the previously found effect (d = 0.74) of communi-
cating social benefit when individual benefit was already
conveyed and when vaccination was immediately access-
ible [10], as was the case in our study. We planned for a
two-tailed logistic model (α = 0.05 & 1-β = 0.80) and
aimed to recruit a total of 159 objectively high-risk pa-
tients, not yet vaccinated for the flu season, for the two
treatment groups. Until we reached our high-risk patient
target, we also recruited low-risk patients, who were less
prevalent among hospital in-patients. We consequently
recruited 159 objectively assessed high-risk and 63 low-
risk patients who were not yet vaccinated for the flu sea-
son as well as 22 patients who were already vaccinated
for the season.
Procedure
One of the researchers, an infectious disease physician,
recruited in-patients on the day of their discharge. By
selecting the next pamphlet on the top of a previously
shuffled stack, patients were randomly assigned to oneof two treatment groups, including either the self-benefit
(51%) or the social-benefit message treatment (49%).
The pamphlets were modelled after actual vaccine pro-
motion messages used by NHS Wales.1 Each treatment
consisted of short text and an abstract figure, facilitating
the transparency of the message to a relatively old and
poorly educated participant pool (see Fig. 2). The top
halves of the two pamphlets were the same and de-
scribed the official criteria for qualifying to be in the risk
group (Fig. 2a). At the bottom half, the text in the self-
benefit treatment indicated that one can gain immunity
against influenza by getting the vaccine (Fig. 2b), while
the text in the social-benefit treatment in addition stated
that gaining immunity would lower the chances of trans-
mitting the disease to others (Fig. 2c). Prompts of “pro-
tect yourself” vs. “protect those around you” and
corresponding emoticons were added to increase the sa-
lience and the clarity of each message [36–38]. Consist-
ent with the pamphlets used by NHS Wales, no
explanation of herd immunity was provided, and both
pamphlets listed the objective risk group criteria and
Table 1 Characteristics of participants in analysis across the
treatment arms (n = 222)
Social-benefit Self-benefit p-value*
Age, median years (mean ± SD) 59 (57 ± 17) 60 (56 ± 18) 0.68
Gender
Female 47 (44) 59 (56) 0.33
Male 59 (51) 57 (49)
Diagnosis at admission
Infectious disease 32 (41) 47 (59) 0.11
Other diagnosis 74 (52) 69 (48)
Ward
Infectious Diseases 22 (42) 31 (58) 0.57
Internal Medicine 46 (53) 41 (47)
Neurology 31 (48) 34 (52)
Other 7 (41) 10 (59)
Education
Less than high school degree 81 (47) 93 (53) 0.50
High school degree or above 25 (52) 23 (48)
Objective risk group (medical assessment)
High 77 (48) 82 (52) 0.75
Low 29 (46) 34 (54)
Subjective risk group (patient perception)
High 26 (51) 25 (49) 0.60
Low 80 (47) 91 (53)
Note. Number of persons (%), unless otherwise indicated. * t-test for age,
χ2 otherwise
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pecially for someone in the risk group.
The pamphlets were given after eliciting written in-
formed consent and between two questionnaires that
sought basic demographic information as well as know-
ledge, experience, attitudes and perceptions regarding
influenza and its vaccine (see Additional file 1 for the
questionnaires). Care was taken to limit any further ver-
bal interaction between the researcher and the patients.
We allowed only two types of patient requests to change
the course of the interaction. First, the researcher uni-
formly recommended the vaccine only if asked for her
advice (30%). Second, the researcher read out the
pamphlet when help was requested (55%) or otherwise
left the room for 5 min. Assistance for reading was
sought primarily due to old age and illiteracy. In these
cases, information flow on the pamphlets was used as
the script. The binary variables of asking for recommen-
dation (Self-benefit: 29%; Social-benefit: 30%) and asking
for help with reading (Self-benefit: 57%; Social-benefit:
52%) did not systematically differ between the two treat-
ment conditions.
Upon the researcher’s return to the room and prior to
the second questionnaire, the decision of whether or notto get the freely provided flu vaccine was elicited. Partic-
ipants who decided to receive the free vaccine were vac-
cinated on site at the end of the study, which comprised
the primary outcome measure.
After the elicitation of vaccination decision, as part
of the second questionnaire (see Additional file 1:
Table S1), reasons for accepting or refusing vaccin-
ation as well as perceptions for being in the high risk-
group (i.e., subjective risk) were measured by asking
“Why do you [not] want to get vaccinated?” (Q2.1) and
“Are you in the risk group for flu?” (Q2.2). In contrast,
patients were categorized as at high objective risk
through medical assessment based on the criteria set
out by the Turkish Ministry of Health at the time of
the study and listed on the pamphlets for defining
high-risk of mortality due to influenza-related ill-
nesses: elderly (≥65), people with various chronic ill-
nesses (e.g., diabetes, asthma). Those who did not
belong to any of these groups formed the low objective
risk group.
As a secondary outcome measure, all participants were
finally given a free vaccination ticket that could be used
by patient’s family and friends within 2 weeks. This was
intended to explore whether social networks can boost
vaccination beyond the hospital setting. Since informa-
tion on the tickets was provided after elicitation of vac-
cination decisions (as well as after the questionnaires),
this additional feature could not influence the primary
outcome measure.Analysis
Twenty-two of the 244 patients (9%) have indicated in
the questionnaires that they were already vaccinated for
the season. Hence, we restricted our analysis of treat-
ment effects to the 222 patients who were not yet vacci-
nated (74% medically assessed to be at high risk) and
who randomly received either the self-benefit (52%) or
the social-benefit (48%) treatment.
We recorded the two types of endogenous variation in
interventions—patients asking for recommendation and
patients asking for the pamphlet to be read out loud for
them—and we control for them as covariates in our ana-
lysis. First, we estimated a simple logistic regression to
find the effect of the prosocial message on vaccination
(Model A). Next, we estimated the moderation of the
treatment effect by objective risk in a logistic model that
includes the experimental treatment, objective risk
group status and their interaction (Model B). Using a
similar interaction model, we then explored the moder-
ation of the treatment effect by perceived risk-group
membership (Model C). To ensure that any effect we
observe is not due to the inclusion of the two aforemen-
tioned covariates [39], we ran these models twice, once
Fig. 2 Experimental Treatments
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the covariates (the unadjusted models).
Finally, we summarized reasons provided for vaccine
acceptance and refusal, examined the overall impact of
the intervention on vaccine uptake, and described the
outcome of the free vaccine ticket program.
Results
Among the 222 patients in the analysis, 159 were medic-
ally assessed to be in the high risk group (72%), whereas
only 51 of 222 patients perceived themselves at high risk
(23%). One hundred and twenty-eight of 222 patients
(58%) miscategorized their risk group status. Among
these patients with inaccurate risk perceptions, 118
underestimated their risk (92%) as compared to 10 pa-
tients who overestimated their risk (8%).
We find no evidence that an emphasis on the vaccina-
tion’s social-benefits increases vaccination as compared
to an emphasis on its self-benefit. In fact, as shown in
Model A in Table 2, vaccination uptake in the self-
benefit treatment was 8 percentage points higher than in
the social-benefit treatment. However, this differencewas not statistically significant (aOR = 1.63, 95% CI 0.90
to 2.95, p = 0.108). As shown in Model B on Table 2, the
difference in vaccination rates between the two treat-
ment groups also did not depend on whether patients
were medically assessed to be at high or low risk of
influenza-related complications (aORHigh / aORLow =
0.88, 95% CI 0.22 to 3.55, p = 0.856).
As shown in Model C on Table 2, exploratory ana-
lysis of perceived risk group status showed a signifi-
cant moderation of the treatment effect among the
overall sample (aORHigh / aORLow = 5.59, 95% CI 1.30
to 24.05, p = 0.021). Specifically, the self-benefit mes-
sage significantly increased vaccination more than the
social-benefit message among those who perceived
themselves as being in the high risk group (aOR =
6.22, 95% CI 1.69 to 22.88, p = 0.006) while it had no
additional effect on vaccination among those who
perceived themselves as being in the low risk group
(aOR = 1.11, 95% CI 0.56 to 2.20, p = 0.758). As seen
in the unadjusted estimates columns on Table 2,
these results are robust to the exclusion of the two
covariates [39].
Table 2 Effect of frames on vaccination and its moderation by objective and subjective risk group
Determinant Vaccinated
patients /
Patients in
category (%)
Adjusted Unadjusted
Subgroup Interaction Subgroup Interaction
aOR [95% CI] aORHigh/aORLow [95% CI] OR [95% CI] ORHigh/ORLow [95% CI]
Model A: Overall Effects of Frames
Social-benefit 36/106 (34.0) 1 1
Self-benefit 49/116 (42.2) 1.63 [0.90–2.95] 1.42 [0.82–2.46]
Model B: Moderation of framing effects by objective risk (medical assessment)
Low Risk Group 15/63 (23.8)
Social-benefit 6/29 (20.7) 1
1
1
1
Self-benefit 9/34 (26.5) 1.82 [0.53–6.17] 1.38 [0.42–4.49]
High Risk Group 70/159 (44.0)
Social-benefit 30/77 (39.0) 1
0.88 [0.22–3.55]
1
1.08 [0.28–4.13]
Self-benefit 40/82 (48.8) 1.60 [0.80–3.17] 1.49 [0.79–2.81]
Model C: Moderation of framing effects by subjective risk (patient perception)
Low Risk Group 62/171 (36.3)
Social-benefit 29/80 (36.3) 1
1
1
1
Self-benefit 33/91 (36.3) 1.11 [0.56–2.20] 1.00 [0.53–1.87]
High Risk Group 23/51 (45.1)
Social-benefit 7/26 (26.9) 1
5.59 [1.30–24.05]
1
4.82 [1.25–18.56]
Self-benefit 16/25 (64.0) 6.22 [1.69–22.88] 4.83 [1.46–15.92]
Note. Table presents vaccination rates and describes corresponding logistic model estimates for three models. Model A describes the overall effect of message
frame treatment on vaccination. Model B describes the interaction between objective risk and treatment, whereas Model C describes the interaction between
subjective risk and treatment. Adjusted estimates include two covariates: doctor’s recommendation and reading of the pamphlet. Unadjusted estimates provide
consistent results. Robust SE. p < 0.05 in bold
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tor’s recommendation, 47 chose to receive vaccination
(65.3%), in comparison to 38 of 150 (25.3%) patients
who did not seek recommendation. This covariate was
significant in all three models (Model A: aOR = 5.52,
95% CI 2.94 to 10.35, p < 0.001). Help with reading of
the pamphlet was sought by 117 patients, 51 of whom
vaccinated (43.6%). Among the 105 patients who did not
seek such help, 34 vaccinated (32.4%). This covariate
was not significant in any of the three models (Model A:
aOR = 1.30, 95% CI 0.71 to 2.38, p = 0.394).
Patients (n = 222) were asked to provide reasons for
their vaccination decisions, and answers were catego-
rized as belonging to one of five acceptance or one of
five refusal reason types (See Table 3). Two coders (OI
& BI) independently assigned each answer to one reasonTable 3 Reasons for vaccine acceptance & refusal
Acceptance (n = 85) Refusal (n = 137)
Self-protection 57 (67.1%) Self-confidence 36 (26.3%)
Recommendation 7 (8.2%) Current-conditions 36 (26.3%)
Others’-protection* 4 (4.7%) Vaccine mistrust 21 (15.3%)
Being in risk group 3 (3.5%) Inexperience 19 (13.9%)
Other or no reason 14 (16.5%) Other or no reason 25 (18.3%)
* Including “protection of self and others”type (Cohen’s kappa: 0.811 for vaccinated & 0.766 for re-
fused). Given the high inter-rater reliability, any discrep-
ancies in ratings were resolved by mutual agreement.
Among those who decided to receive the vaccine as part
of the study, the overwhelming majority cited “self-pro-
tection” as the reason (67%), whereas only four patients
referred to protection of others (5%). Among those who
decided not to receive the vaccine, responses that
reflected confidence in one’s current health status such
as “I am healthy”, “I don’t need vaccines”, and “I never
catch the flu” were categorized as “self-confident”. The
most common reasons for rejection were found to be
“self-confidence” (26%), “current health conditions” such
as receiving other treatments (26%), “vaccine mistrust”
(15%) and “lack of experience or knowledge regarding
the vaccine” (14%). Although “self-protection” was a
more prevalent reason in the self-benefit (61%) than in
the social-benefit treatment (39%), no statistically signifi-
cant difference due to experimental manipulations was
observed for any category in either acceptance or refusal
reasons (Fisher’s exact tests: p = 0.423 and p = 0.738
respectively).
As a consequence of our intervention, 85 of 222 (38%)
patients who were not yet vaccinated for the flu season
chose to receive vaccination. Including the 22 partici-
pants who were already vaccinated at the start of the
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44%. These values indicate substantial improvements
over previous year rate of 16% vaccination among all
244 study participants (based on questionnaire item
Q1.7, see SI) as well as over the 2006 vaccination rates
of 6–19% among high-risk groups in Turkey [40].
None of the 244 free vaccination tickets were brought
back to the hospital to receive free vaccination. Though
we have no way of knowing, we conjecture that patients
either failed to pass the tickets on to others or when they
did, they failed to persuade others to vaccinate. Either of
these cases can be interpreted as evidence against strong
prosocial motives in vaccination among a high-risk
group.
Discussion
Principle findings
This field experiment provides the first behavioural test
of the prosocial vaccination hypothesis among a pre-
dominantly high-risk patient population. This hypothesis
builds on tests of vaccination intentions in hypothetical
scenarios [10–12], as well as on domain-general evi-
dence that people care about the well-being of others
[14, 15]. However, evidence suggests that an emphasis
on social-benefits may not be as effective in a high-risk
group. Indeed, direct self-benefit motives are often rela-
tively stronger than social-benefit motives, especially
when people feel personally at risk [22, 23]. Moreover,
no previous study has provided decisive evidence from
the field that prosocial messages increase vaccination
coverage [9], and it has been suggested that an emphasis
on self-protection may be more successful in increasing
vaccination than an emphasis on its social benefits [32].
We compared the effectiveness of two alternative mes-
sages for motivating vaccination among a high-risk
group facing real stakes. Failing to provide evidence for
the prosocial vaccination hypothesis, the social-benefit
message was not found to increase vaccination as com-
pared to the self-benefit message. Although the differ-
ence was not statistically significant, average vaccination
rate was 8 percentage points higher among those who
received the self-benefit message than those who re-
ceived the social-benefit message.
Furthermore, through our exploratory analysis, we
found the self-benefit message to be significantly more ef-
fective among patients who perceived themselves to be in
the high risk group. This is consistent with both empirical
evidence that high-risk perceptions motivate preventive
health behaviour such as vaccination [8, 19, 22, 23] and
with theoretical evidence that self-focused message will be
affectively more salient for those with higher perceptions
of risk group membership [21]. Moreover, patients who
accepted the vaccination provided reasons more fre-
quently referring to the self-benefits of vaccination, whilesocial-benefit motives were rarely mentioned. In contrast
to perceptions of risk group membership, objective risk
group membership did not moderate the effect of the
messages on vaccine uptake. We invite future research to
test our exploratory finding that high risk perceptions
dampen the positive effects of social benefit messages.
A majority of our participants had risk misperceptions,
most of whom had underestimated their risk. Risk group
misperceptions have also been found to be relatively
high in a random sample of the US population (34%),
where most misperceptions were similarly due to under-
estimation (96%) [33]. These results suggest that under-
standing the determinants of risk misperceptions in
general and risk underestimation in particular are likely
to provide crucial insights into vaccination avoidance.
Our simple intervention achieved substantially higher
influenza vaccine uptake as compared with high risk
reference groups. Factors commonly present in hospi-
tals such as the free provision of the vaccine, the low
transaction costs of in-patients, the information pro-
vided in the pamphlets, and the presence of a medical
authority are likely to have contributed to this outcome.
Nevertheless, even when compared with the rate we
achieved with our intervention, vaccination rates
among high-risk groups in Western countries are sub-
stantially higher (65% in the US and 74% in the UK for
ages 65 and older in 2011–2012) [3]. Prevalence of
anti-vaccination attitudes, fear of side-effects and mis-
placed self-confidence of patients in Turkey may well
explain this discrepancy [41–43].Limitations of the study
The difficulty of studying actual vaccination of natural
risk groups in the field resulted in four limitations. First,
we cannot identify the isolated effect of each message on
vaccination uptake due to the lack of a “no intervention”
control condition. Given our resources, we opted to
maximize the number of observations in the two treat-
ments. Second, description of the mechanism of herd
immunity was not provided because our materials were
adapted from pamphlets employed by an actual national
health service, which refrained from a detailed explan-
ation. Descriptions of herd-immunity have been shown
to increase vaccination intentions [11], and it remains to
be tested in promoting actual vaccination behavior
among patients. Third, we were ethically obliged to
present risk group criteria to both treatment groups,
which may have resulted in the social-benefit message
being mixed with information pertaining to self-benefit.
Finally, as we explain in the next paragraph, the moder-
ation of treatment effect by perceptions of risk group
membership can be endogenous, although our analysis
points to no such confounds.
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cination decisions to avoid biasing of these decisions by the
elicitation procedure. However, this design choice opens
the measure to possible post hoc rationalizations, in par-
ticular, to patients’ inaccurate declarations that “they are
not at risk” as justifications for their refusal to vaccinate
[8]. We did not find evidence for such a confound: among
those who were medically assessed to be at high risk, the
accuracy of risk perceptions was not significantly different
(χ2 test; P = 0.729) between those who refused (25%) and
accepted vaccination (27%). Similarly, using post-treatment
variables as covariates may bias model estimates if treat-
ments affect these variables. Again, we find no influence of
treatments on risk group perceptions (χ2 test; P = 0.598).
Conclusions
Public authorities such as the CDC and the European
Council prioritize the vaccination of those at most risk
against influenza [3, 4]. Our field experiment showed that
simple motivational interventions, when implemented in a
real clinical setting, can effectively target and substantially
increase the vaccination of such high priority groups. We
also found that the prosocial vaccination hypothesis does
not apply to high-risk groups. These findings do not ne-
cessarily contradict previous evidence supporting the hy-
pothesis because social-protection afforded by vaccination
can be more valuable than self-protection among the gen-
eral public who are personally less at risk or among other
cultures with stronger prosocial attitudes. Instead, in line
with the impetus of the stratified medicine approach [44,
45], our results suggest a significant boundary condition
on the prosocial vaccination hypothesis. We therefore sug-
gest that heterogeneity of risk groups and their perceptions
should be taken into account when formulating vaccine
advocacy policies. In particular, professional communica-
tions that aim to promote vaccination among high risk
groups may be more effective with an emphasis on vacci-
nation’s self-benefit rather than its social benefits. More
generally, our study highlights the importance of validating
theoretical and laboratory findings in the field, and shows
that a stratified approach to behavioural interventions can
substantially improve the efficiency of public policies.
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